Journal
FEBS LETTERS
Volume 591, Issue 22, Pages 3771-3780Publisher
WILEY
DOI: 10.1002/1873-3468.12878
Keywords
biased ligands; E-type prostanoid 4 receptors; PGE(1); PGE(2); PGE(3); TCF/beta-catenin signaling
Funding
- MEXT KAKENHI [JP17K08308]
- Grants-in-Aid for Scientific Research [16K08542, 17H04316, 17K08308] Funding Source: KAKEN
Ask authors/readers for more resources
The 2-series of prostaglandin E (PGE(2)) is regarded as a pro-cancer prostanoid, whereas the 1-series (PGE(1)) and the 3-series ( PGE(3)) are considered to act as anti-cancer prostanoids. In the present study, we provide possible reasons why PGE(1) and PGE(3), but not PGE(2), exert anti-cancer effects by focusing on each diverged E-type prostanoid (EP)(4) receptor-mediated signaling pathway. PGE(1), PGE(2) and PGE(3) function as full agonists in terms of Gas-and Gai-protein-mediated signaling. However, PGE(1) and PGE(3) function as partial agonists of T-cell factor (TCF)/beta-catenin (beta-cat)-mediated activity, the well-known cancer-related signaling pathway. Furthermore, pretreatment with PGE(1) or PGE(3) almost completely reduces PGE(2)-induced TCF/beta-cat activity. These results provide a plausible reason why PGE(1) and PGE(3) function as anti-cancer prostanoids as a result of novel biased activity for EP4 receptors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available